Abstracts tagged "statins and systemic lupus erythematosus (SLE)"

Abstract Number: 1674 • 2017 ACR/ARHP Annual Meeting
Combining Medications That Lower Systemic Oxidative Stress Is Associated with Less Atherosclerosis in Systemic Lupus Erythematosus
Jim C. Oates, Medical Service, Ralph H. Johnson VA Medical Center, Charleston, SC; Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: No single medication has been demonstrated as effective in reducing atherosclerosis or cardiovascular events in systemic lupus erythematosus (SLE), possibly due to the…
Abstract Number: 772 • 2016 ACR/ARHP Annual Meeting
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Givenchy Maree Garcia, Annalyn Urbano and Evelyn Salido, Section of Rheumatology, University of the Philippines - Philippine General Hospital, Manila, Philippines
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…
Abstract Number: 887 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez¹, Mª Angeles Aguirre², Nuria Barbarroja¹, Tomás Cerdó-Ráez³, Maria Laura Bertolaccini⁴, Munther A. Khamashta⁵, Antonio Rodriguez-Ariza⁶, Yolanda Almaden⁷, Husam Khraiwesh⁸, Jose Antonio Gonzalez-Reyes⁹, Jose Manuel Villalba¹⁰, Eduardo Collantes¹¹ and Mª Jose Cuadrado¹², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Imibic, Córdoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁷Imibic, Códoba, Spain, ⁸UCO, Córdoba, Spain, ⁹Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ¹⁰Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ¹¹Rheumatology, Hospital Reina Sofia, Cordoba, Spain, ¹²Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…
Abstract Number: 1824 • 2012 ACR/ARHP Annual Meeting
Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study
Thomas W. Schmidt¹, Daniel F. Battafarano¹, Christopher R. Frei², Eric M. Mortensen³ and Ishak Mansi⁴, ¹Rheumatology, San Antonio Military Medical Center, San Antonio, TX, ²Pharmacotherapy Education and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Internal Medicine, San Antonio Military Medical Center, San Antonio, TX
Background/Purpose: Due to their anti-inflammatory effects, statins were proposed to lower the incidence of connective tissue diseases (CTD). The objective of this study is to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].